New York University Skip to Content Skip to Search Skip to Navigation Skip to Sub Navigation

Dentistry’s Xin Li To Investigate if Diabetes Drug Prevents Prostate Cancer

September 17, 2013

By Elyse Bloom


Xin Li, an assistant professor of basic science and craniofacial biology at the College of Dentistry, has received a grant from the National Cancer Institute of the National Institutes of Health to conduct a preclinical study of the potential of metformin, an oral anti-diabetic drug, to prevent the development and progression of prostate cancer, the second leading cause of cancer-related deaths in American men.


Current treatment techniques for prostate cancer are mostly palliative with poor prognosis. However, epidemiological studies indicate that patients taking metformin have lower prostate cancer risk and better prognosis.


“Our central hypothesis is that metformin acts as a novel chemo-preventive agent to restrict the initiation and progression of prostate cancer,” says Li. “Our preliminary data demonstrate that metformin reduces the cancer-promoting MYC oncogene levels both in vitro and in vivo.”
The MYC oncogene produces a DNA-binding protein that promotes cancerous cell growth and also alters prostate tumor sensitivity to inhibitors that regulate cell growth.


Li and her team will use mice having a regulator gene found in many cancers to examine the inhibitory effect of metformin on prostate cancer progression and also to define the epigenetic enzyme alterations that occur in metformin-treated prostate cancer.


“We postulate that our investigation of a novel combined cancer prevention therapy using metformin and mTOR inhibitors will yield findings that can be translated into clinical research, thereby providing guidance for prostate cancer prevention, early diagnosis, and treatment of this disease,” says Li.

Type: Article

Dentistry’s Xin Li To Investigate if Diabetes Drug Prevents Prostate Cancer

Search News



NYU In the News

Entrepreneurship Lab Opens at NYU

Crain’s New York Business covered the opening of the Mark and Debra Leslie Entrepreneurial eLab, which will be the headquarters for NYU’s Entrepreneurial Institute and all of the University’s programs aimed at promoting innovation and startups.

A Globalizer for N.Y.U. in Abu Dhabi

The New York Times profiled Bill Bragin who will become the first executive artistic director of NYU Abu Dhabi’s new performing arts center.

Think Tank to Ponder a Future for Ballet

The New York Times profiled Jennifer Homans, the director of NYU’s new Center for Ballet and the Arts.

The Brilliant Ten: Jonathan Viventi Builds Devices That Decode Thoughts

Popular Science named Assistant Bioengineering Professor Jonathan Viventi as one of its “brilliant ten” for his research into brain implants that could one day halt epileptic episodes:

Living and Leaving the Dream: Adrian Cardenas’ Journey from the Major Leagues to College

The New York Times ran a feature on Adrian Cardenas, a former major league baseball player who is now studying philosophy and creating writing at NYU.

NYU Footer